Ingersoll Rand completed the acquisition of ILC Dover from New Mountain Capital for $2.325bn.

Ingersoll Rand, a global provider of mission-critical flow creation and industrial solutions, completed the acquisition of ILC Dover, a company specializing in the design and production of highly innovative solutions for biopharmaceutical, pharmaceutical, and medical device markets, from New Mountain Capital, a leading growth-oriented investment firm, for $2.325bn. “This acquisition is the next phase of our long-term vision to expand into higher-growth end markets like life sciences. I am incredibly excited to partner with Corey and the outstanding team at ILC, whom we’ve admired for their innovative products and decades of experience in life sciences, to enhance our presence in key workflows and applications,” Vicente Reynal, Ingersoll Rand Chairman and CEO.